Compare Moderna, Inc. (MRNA) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prospect Capital Corporation — how do they compare? Moderna, Inc. trades at $135.84 (market cap $56.02B), while Prospect Capital Corporation trades at $2.19 (market cap $1.13B). The key difference: Moderna, Inc. is far larger — about 49.6× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 19.09% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PSEC | |
|---|---|---|
Market Cap | $56.02B | $1.13B |
Sector | Health | Financials |
52-Week High | $174.38 | $3.05 |
52-Week Low | $22.36 | $2.11 |
Enterprise Value | $52.17B | — |
Dividend Yield | — | 19.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Prospect Capital (PSEC) trades at $2.19, down 1.79% recently, with a bearish technical signal and deep discount to book value (P/B 0.39). The company reported negative revenue and net income for 2025, though quarterly EPS has beaten estimates. It maintains a high dividend yield, paying $0.04 monthly, but faces net cash outflow and portfolio contraction concerns highlighted in recent news.
Outlook remains cautious due to financial deterioration and NAV erosion risks, offset by high yield and valuation discount. Analyst consensus is mixed with 25% buy ratings, reflecting divided opinion on recovery potential versus ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
